Inventor · disambiguated record
Felix Cleemann
Also filed as: CLEEMANN FELIX
23 granted patents·23 pending applications·200 citations·filing 2006–2024
95Inventor score
Files withASCENDIS PHARMA GROWTH DISORDERS AS22ASCENDIS PHARMA BONE DISEASES AS14ASCENDIS PHARMA AS3CLEEMANN FELIX2ASCENDIS PHARMA RELAXIN DIV AS1
Top patents by PatentIndex Score
46 records- 0197US11154593B2CNP prodrugs with large carrier moietiesASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2021·Granted Oct 26, 2021·13 cites·28 claims
- 0297US10835578B2CNP prodrugs with large carrier moietiesASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2017·Granted Nov 17, 2020·21 cites·20 claims
- 0396US11890326B2Controlled-release PTH compoundASCENDIS PHARMA BONE DISEASES AS·Filed 2022·Granted Feb 6, 2024·5 cites·11 claims
- 0496US11793861B2PTH prodrugsASCENDIS PHARMA BONE DISEASES AS·Filed 2022·Granted Oct 24, 2023·5 cites·15 claims
- 0595US12156917B2CNP prodrugs with carrier attachment at the ring moietyASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2022·Granted Dec 3, 2024·2 cites·13 claims
- 0695US11918628B2Controlled-release PTH compoundASCENDIS PHARMA BONE DISEASES AS·Filed 2023·Granted Mar 5, 2024·4 cites·9 claims
- 0795US11857603B2PTH compounds with low peak-to-trough ratiosASCENDIS PHARMA BONE DISEASES AS·Filed 2022·Granted Jan 2, 2024·5 cites·12 claims
- 0895US8906847B2Prodrug comprising a drug linker conjugateCLEEMANN FELIX·Filed 2009·Granted Dec 9, 2014·86 cites·37 claims
- 0993US12083182B2Controlled-release CNP agonists with increased NEP stabilityASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2021·Granted Sep 10, 2024·3 cites·15 claims
- 1092US11759504B2PTH compounds with low peak-to-trough ratiosASCENDIS PHARMA BONE DISEASES AS·Filed 2017·Granted Sep 19, 2023·6 cites·12 claims
- 1190US11389510B2Controlled-release CNP agonists with low initial NPR-B activityASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2017·Granted Jul 19, 2022·5 cites·6 claims
- 1289US11413351B2CNP prodrugs with carrier attachment at the ring moietyASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2017·Granted Aug 16, 2022·7 cites·17 claims
- 1389US2025127797A1Prodrug comprising a drug-linker conjugateASCENDIS PHARMA AS·Filed 2024·Application pending·0 cites
- 1489US2025127859A1Cnp prodrugs with large carrier moietiesASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2024·Application pending·0 cites
- 1589US2025268988A1PTH ProdrugsASCENDIS PHARMA BONE DISEASES AS·Filed 2024·Application pending·0 cites
- 1688US12239689B2Controlled-release CNP agonists with low initial NPR-B activityASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2022·Granted Mar 4, 2025·1 cites·10 claims
- 1788US11389511B2Controlled-release CNP agonists with reduced side-effectsASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2017·Granted Jul 19, 2022·7 cites·16 claims
- 1887US12214020B2PTH prodrugsASCENDIS PHARMA BONE DISEASES AS·Filed 2023·Granted Feb 4, 2025·0 cites·9 claims
- 1987US2025090671A1Cnp prodrugsASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2024·Application pending·0 cites
- 2086US2024316153A1Cnp prodrugs with large carrier moietiesASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2024·Application pending·0 cites
- 2185US11311604B2Controlled-release CNP agonists with low NPR-C bindingASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2017·Granted Apr 26, 2022·6 cites·10 claims
- 2285US9457066B2Prodrugs comprising an insulin linker conjugateSANOFI AVENTIS DEUTSCHLAND·Filed 2015·Granted Oct 4, 2016·6 cites·24 claims
- 2382US2025121074A1Cnp prodrugs with carrier attachment at the ring moietyASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2024·Application pending·0 cites
- 2481US2023321198A1Dosage Regimen for a Controlled-Release PTH CompoundASCENDIS PHARMA BONE DISEASES AS·Filed 2023·Application pending·0 cites
- 2580US9265723B2Long acting insulin compositionSPROGOE KENNETT·Filed 2010·Granted Feb 23, 2016·11 cites·50 claims
- 2678US9133276B2Prodrugs comprising an exendin linker conjugateCLEEMANN FELIX·Filed 2011·Granted Sep 15, 2015·6 cites·26 claims
- 2777US2022296682A1Cnp prodrugs with large carrier moietiesASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2021·Application pending·0 cites
- 2877US2022008516A1PTH ProdrugsASCENDIS PHARMA BONE DISEASES AS·Filed 2021·Application pending·0 cites
- 2977US2025090639A1Controlled-release cnp agonists with low initial npr-b activityASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2024·Application pending·0 cites
- 3076US2025041431A1Controlled-release cnp agonists with increased nep stabilityASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2024·Application pending·0 cites
- 3173US2023116746A1Cnp prodrugsASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2022·Application pending·0 cites
- 3272US2021077584A1Cnp prodrugs with large carrier moietiesASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2020·Application pending·0 cites
- 3371US2020360487A1Pth prodrugsASCENDIS PHARMA BONE DISEASES AS·Filed 2020·Application pending·0 cites
- 3471US2020376089A1Pth prodrugsASCENDIS PHARMA BONE DISEASES AS·Filed 2020·Application pending·0 cites
- 3566US9138462B2Prodrugs comprising an insulin linker conjugateRAU HARALD·Filed 2010·Granted Sep 22, 2015·1 cites·27 claims
- 3666US2021069339A1Cnp prodrugsASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2020·Application pending·0 cites
- 3764US2015057221A1Prodrug comprising a drug linker conjugateASCENDIS PHARMA AS·Filed 2014·Application pending·0 cites
- 3863US2022211817A1Controlled-release cnp agonists with low npr-c bindingASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2022·Application pending·0 cites
- 3961US2020276276A1PTH ProdrugsASCENDIS PHARMA BONE DISEASES AS·Filed 2017·Application pending·0 cites
- 4059US2019255183A1Cnp prodrugsASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2019·Application pending·0 cites
- 4150US2017368189A1Cnp prodrugsASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2016·Application pending·0 cites
- 4248US12453778B2Incremental dose finding in controlled-release PTH compoundsASCENDIS PHARMA BONE DISEASES AS·Filed 2017·Granted Oct 28, 2025·0 cites·8 claims
- 4343US12403182B2Liquid pharmaceutical formulations of PTH conjugatesASCENDIS PHARMA BONE DISEASES AS·Filed 2020·Granted Sep 2, 2025·0 cites·8 claims
- 4443US2016296600A1Relaxin ProdrugsASCENDIS PHARMA RELAXIN DIV AS·Filed 2014·Application pending·0 cites
- 4539US2009187017A1Process for preparing enantiomerically enriched beta-amino acid derivativesEVONIK DEGUSSA GMBH·Filed 2006·Application pending·0 cites
- 4637US11633487B2Prodrugs comprising an aminoalkyl glycine linkerASCENDIS PHARMA AS·Filed 2015·Granted Apr 25, 2023·0 cites·19 claims
Join the waitlist — get patent alerts
Get an alert when Felix Cleemann files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →